Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18891555 | MULTIPLEX CELLULAR ASSAYS FOR SCREENING AND QUALITY ASSESSMENT OF ENGINEERED CELLS | September 2024 | December 2025 | Abandon | 15 | 1 | 1 | No | No |
| 18309452 | USES FOR AND ARTICLE OF MANUFACTURE INCLUDING HER2 DIMERIZATION INHIBITOR PERTUZUMAB | April 2023 | September 2025 | Allow | 29 | 4 | 0 | Yes | Yes |
| 18178854 | ANTI-TMEM-180 ANTIBODY, ANTICANCER AGENT, AND TEST METHOD FOR CANCER | March 2023 | February 2026 | Abandon | 35 | 1 | 0 | No | No |
| 17932147 | ANTIBODIES AGAINST SARS-COV-2 AND METHODS OF USING THE SAME | September 2022 | March 2026 | Abandon | 42 | 1 | 0 | No | No |
| 17872494 | Anti-TIGIT Antibodies | July 2022 | September 2025 | Allow | 38 | 3 | 0 | No | No |
| 17283690 | Methods of Treating Rheumatoid Arthritis | April 2021 | January 2026 | Abandon | 57 | 2 | 1 | No | No |
| 17054043 | METHOD FOR PRODUCING T CELLS MODIFIED BY CHIMERIC ANTIGEN RECEPTOR | November 2020 | January 2026 | Allow | 60 | 4 | 1 | Yes | No |
| 16999578 | ANTI-CD47 ANTIBODIES AND USES THEREOF | August 2020 | March 2021 | Allow | 7 | 0 | 1 | Yes | No |
| 16916220 | PEPTIDES AND COMBINATION THEREOF FOR USE IN THE IMMUNOTHERAPY AGAINST CANCERS | June 2020 | May 2021 | Allow | 10 | 1 | 0 | No | No |
| 16804548 | PEPTIDES AND COMBINATION THEREOF FOR USE IN THE IMMUNOTHERAPY AGAINST CANCERS | February 2020 | January 2021 | Allow | 11 | 1 | 0 | Yes | No |
| 16797778 | PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LEUKEMIAS AND OTHER CANCERS | February 2020 | June 2021 | Allow | 15 | 2 | 0 | Yes | No |
| 16794035 | PEPTIDES AND COMBINATION THEREOF FOR USE IN THE IMMUNOTHERAPY AGAINST CANCERS | February 2020 | February 2021 | Allow | 12 | 2 | 0 | Yes | No |
| 16793721 | PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LEUKEMIAS AND OTHER CANCERS | February 2020 | January 2021 | Allow | 11 | 2 | 0 | Yes | No |
| 16320719 | PSEUDO-VIRAL PARTICLES AND USES OF SAME | January 2019 | December 2025 | Abandon | 60 | 5 | 1 | Yes | Yes |
| 15961699 | NUCLEIC ACID ENCODING DUAL FC ANTIGEN BINDING PROTEINS | April 2018 | May 2020 | Allow | 25 | 1 | 0 | Yes | No |
| 15949884 | PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LEUKEMIAS AND OTHER CANCERS | April 2018 | December 2020 | Allow | 32 | 2 | 1 | Yes | No |
| 14977325 | MONOCLONAL ANTI-GT 468 ANTIBODIES FOR TREATMENT OF CANCER | December 2015 | October 2019 | Allow | 46 | 4 | 0 | Yes | No |
| 14958980 | ANTI-CD38 HUMAN ANTIBODIES AND USES THEREOF | December 2015 | June 2017 | Allow | 18 | 3 | 1 | Yes | No |
| 14800162 | STABILIZED PEPTIDE FRAGMENTS FROM NUCLEOREDOXIN X1 AND USES THEREOF | July 2015 | October 2017 | Allow | 27 | 4 | 1 | Yes | No |
| 14606683 | METHOD OF TREATING DISORDERS REQUIRING DESTRUCTION OR REMOVAL OF CELLS | January 2015 | April 2024 | Abandon | 60 | 12 | 1 | No | Yes |
| 14505595 | Multivalent Antibody Complexes Targeting IGF-1R Show Potent Toxicity Against Solid Tumors | October 2014 | October 2017 | Allow | 36 | 9 | 1 | No | No |
| 14449975 | METHODS FOR IDENTIFICATION OF SITES FOR IGG CONJUGATION | August 2014 | January 2017 | Allow | 29 | 2 | 1 | Yes | No |
| 14199760 | ANTI-C-MET Tandem Fc Bispecific Antibodies | March 2014 | August 2016 | Allow | 29 | 1 | 1 | Yes | No |
| 13811883 | COVALENTLY-ASSOCIATED DIABODY COMPLEXES THAT POSSESS CHARGED COIL DOMAINS AND THAT ARE CAPABLE OF ENHANCED BINDING TO SERUM ALBUMIN | July 2013 | September 2017 | Allow | 56 | 3 | 1 | Yes | No |
| 13891652 | ANTIBODY FOR DETECTING DNA DAMAGE IN CELLS UTILIZING CELL MEMBRANE SURFACE ANTIGEN LY6D | May 2013 | October 2015 | Allow | 29 | 2 | 1 | Yes | No |
| 13886766 | HIGHLY EFFECTIVE ANTI-CADHERIN ANTIBODY FOR INDUCTION OF ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY IN VIVO | May 2013 | January 2015 | Allow | 21 | 1 | 0 | Yes | No |
| 13797374 | NOTCH1 BINDING AGENTS AND METHODS OF USE THEREOF | March 2013 | May 2015 | Allow | 26 | 2 | 0 | Yes | No |
| 13636277 | MONOCLONAL ANTIBODIES FOR TREATMENT OF CANCER | December 2012 | August 2015 | Allow | 35 | 3 | 1 | Yes | No |
| 13466433 | 1B20 PCSK9 ANTAGONISTS | May 2012 | October 2014 | Allow | 29 | 2 | 1 | Yes | No |
| 13456354 | PODXL Protein in Colorectal Cancer | April 2012 | December 2014 | Allow | 31 | 5 | 0 | Yes | Yes |
| 13318422 | HIGHLY EFFECTIVE ANTI-CADHERIN ANTIBODY FOR INDUCTION OF ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY IN VIVO | February 2012 | January 2013 | Allow | 15 | 2 | 0 | Yes | No |
| 13265490 | IMMUNOGENIC EPITOPES OF NGEP ANTIGEN | November 2011 | January 2014 | Allow | 27 | 2 | 1 | Yes | No |
| 13111685 | NEOPLASM SPECIFIC ANTIBODIES AND USES THEREOF | May 2011 | June 2013 | Allow | 25 | 2 | 1 | Yes | No |
| 13005966 | Notch1 Binding Agents and Methods of Use Thereof | January 2011 | May 2014 | Allow | 40 | 3 | 1 | Yes | No |
| 12913300 | NOVEL ANTIBODIES FOR THE TREATMENT OF HIV | October 2010 | March 2015 | Allow | 53 | 4 | 1 | Yes | No |
| 12921954 | PEPTIDES AND APTAMERS THEREOF AS SPECIFIC MODULATORS OF MUTANT P53 FUNCTION | September 2010 | May 2014 | Allow | 44 | 2 | 1 | Yes | No |
| 12763676 | AG-205 FOR THE TREATMENT OF BREAST CANCER | April 2010 | February 2017 | Allow | 60 | 6 | 1 | Yes | No |
| 12710442 | HUMANIZED ANTIBODIES THAT BIND TO CD19 AND THEIR USES | February 2010 | October 2013 | Allow | 44 | 3 | 1 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner ALLEN, MICHAEL D.
With a 0.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 0.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner ALLEN, MICHAEL D works in Art Unit 1671 and has examined 33 patent applications in our dataset. With an allowance rate of 90.9%, this examiner has an above-average tendency to allow applications. Applications typically reach final disposition in approximately 29 months.
Examiner ALLEN, MICHAEL D's allowance rate of 90.9% places them in the 75% percentile among all USPTO examiners. This examiner has an above-average tendency to allow applications.
On average, applications examined by ALLEN, MICHAEL D receive 3.00 office actions before reaching final disposition. This places the examiner in the 86% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by ALLEN, MICHAEL D is 29 months. This places the examiner in the 62% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.
Conducting an examiner interview provides a +46.6% benefit to allowance rate for applications examined by ALLEN, MICHAEL D. This interview benefit is in the 91% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 14.0% of applications are subsequently allowed. This success rate is in the 9% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 56.0% of cases where such amendments are filed. This entry rate is in the 82% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants request a pre-appeal conference (PAC) with this examiner, 100.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 70% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 33.3% of appeals filed. This is in the 4% percentile among all examiners. Of these withdrawals, 100.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner rarely withdraws rejections during the appeal process compared to other examiners. If you file an appeal, be prepared to fully prosecute it to a PTAB decision. Per MPEP § 1207, the examiner will prepare an Examiner's Answer maintaining the rejections.
When applicants file petitions regarding this examiner's actions, 40.0% are granted (fully or in part). This grant rate is in the 29% percentile among all examiners. Strategic Note: Petitions show below-average success regarding this examiner's actions. Ensure you have a strong procedural basis before filing.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 2% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 3% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.